Type 2 Diabetes, Vitamin D Deficiency
Conditions
Keywords
Type 2 diabetes, Vitamin D deficiency, Glycemic control
Brief summary
Using a randomized, placebo-controlled trial design in subjects with vitamin D deficiency, the investigators propose to determine if vitamin D treatment improves glycemic control in vitamin D deficient subjects with T2DM. The investigators hypothesize that oral vitamin D treatment will improve glycemic control and ß-cell function in vitamin D deficient AA subjects with T2DM. The investigators further hypothesize that maintaining serum 25(OH)D concentrations above 20 ng/ml with oral supplementation of vitamin D will have additional glycemic control effects.
Detailed description
Current literature suggests that 25-hydroxyvitamin D (25(OH)D) is inversely related to risk of type 2 diabetes mellitus (T2DM). African Americans (AA) have significantly less 25(OH)D concentrations, greater chances of poor glycemic control compared to European Americans (EA). The primary objective is to evaluate if the differences in glycemic control in children with type 2 diabetes are explained by differences in serum concentrations of 25(OH)D. A secondary aim is to demonstrate that subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) and T2DM who receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) have greater improvement than subjects who receive placebo in glycemic control, as measured by HbA1c and endogenous insulin secretion, as assessed by area under the concentration-time curve (AUC) for mixed meal-stimulated C peptide, at 3 months after study drug administration. Research design: Randomized, placebo-controlled, double blind study design in children with T2DM and vitamin D deficiency. Glycemic control will be determined by HbA1C levels, fasting glucose and area under the curve (AUC) for glucose after a mixed meal tolerance test (MMTT). Measures of beta cell function will be determined by AUC for c-peptide and glucose after MMTT. This study is warranted in AA adolescents with T2DM as any positive interventions could have life long impact and will lead to future larger clinical trials.
Interventions
DIETARY_SUPPLEMENTVitamin D2
Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
OTHERSugar pill
1. group: vitamin D2 50000 IU weekly once for 8 weeks 2. nd group: placebo weekly once for 8 weeks
Sponsors
University of Alabama at Birmingham
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 DM with acanthosis * African American * 12-18 years * BMI\> 85% * Tanner Stage \> 4
Exclusion criteria
* Those taking vitamin D * Pregnancy * Those with chronic health conditions other than diabetes * Those who are deemed medically unstable to participate in research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1C | 3 -4 months | glycemic control |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC for c-peptide and glucose after MMTT | 3- 4months | Area under the curve (AUC) for glucose after a mixed meal tolerance test (MMTT) |
Countries
United States
Outcome results
None listed